Institutional shares held 61.8 Million
85.8K calls
86.4K puts
Total value of holdings $598M
$829K calls
$835K puts
Market Cap $698M
72,160,000 Shares Out.
Institutional ownership 85.65%
# of Institutions 198


Latest Institutional Activity in RCUS

Top Purchases

Q2 2025
Point72 Asset Management, L.P. Shares Held: 5.97M ($57.7M)
Q2 2025
Suvretta Capital Management, LLC Shares Held: 3.69M ($35.7M)
Q2 2025
Integral Health Asset Management, LLC Shares Held: 300K ($2.9M)
Q2 2025
Pdt Partners, LLC Shares Held: 389K ($3.76M)
Q2 2025
Bank Of America Corp Shares Held: 498K ($4.81M)

Top Sells

Q2 2025
Woodline Partners LP Shares Held: 4M ($38.7M)
Q2 2025
Decheng Capital LLC Shares Held: 160K ($1.55M)
Q2 2025
Parkman Healthcare Partners LLC Shares Held: 600K ($5.8M)
Q2 2025
Goldman Sachs Group Inc Shares Held: 648K ($6.27M)
Q2 2025
Bnp Paribas Asset Management Holding S.A. Shares Held: 1.4M ($13.5M)

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.


Insider Transactions at RCUS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.93M Shares
From 17 Insiders
Grant, award, or other acquisition 524K shares
Open market or private purchase 1.4M shares
Sell / Disposition
140K Shares
From 10 Insiders
Payment of exercise price or tax liability 133K shares
Open market or private sale 3.8K shares
Sale (or disposition) back to the issuer 3.01K shares

Track Institutional and Insider Activities on RCUS

Follow Arcus Biosciences, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RCUS shares.

Notify only if

Insider Trading

Get notified when an Arcus Biosciences, Inc. insider buys or sells RCUS shares.

Notify only if

News

Receive news related to Arcus Biosciences, Inc.

Track Activities on RCUS